Telix Pharmaceuticals (TLX) Stock: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$9.45
-0.58 (-5.78%)
▼
5d:
-10.6%
30d:
-16.15%
90d:
-7.53%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Jul 02, 2026
0d
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TLX is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TLX is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $9.45, which is considered oversold relative to its 30-day fair value range of $10.62 to $11.89. From a valuation perspective, the stock is trading at a discount (Forward PE: -260.5) compared to its historical average (35.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $9.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.77 (+107.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $9.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.77 (+107.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.62 -
$11.89
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.8%)
- BULLISH: Trading 107.1% below Wall St target ($20.77)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.62 -
$11.89
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.92
Resistance Level
$11.39
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-260.52
Wall Street Target
$20.77
(+107.1%)
Revenue Growth (YoY)
22.3%
Profit Margin
3.8%
PE vs Historical
-260.5 vs 35.2
CHEAP
Share & Embed Analysis
Last updated: October 22, 2026 10:12 AM ET
Data refreshes hourly during market hours. Next update: 11:12 AM
Data refreshes hourly during market hours. Next update: 11:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 66 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 73 BUY |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 63 BUY |
